CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NitazoxanideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (17)

Name (Synonyms) Correlation
drug2665 Vitamin Super B-Complex Wiki 0.50
drug565 Chloroquine diphosphate Wiki 0.35
drug1708 Other drugs Wiki 0.35
drug2202 Sars-Cov-2 serology Wiki 0.35
drug2004 RO6953958 Wiki 0.35
drug1578 Natural Honey Wiki 0.35
drug560 Chloroquine Wiki 0.25
drug1592 Niclosamide Wiki 0.25
drug601 Colchicine Wiki 0.25
drug3005 standard care Wiki 0.20
drug2300 Standard Care Wiki 0.18
drug1270 Ivermectin Wiki 0.17
drug1822 Placebo Wiki 0.14
drug1484 Methylprednisolone Wiki 0.11
drug923 Favipiravir Wiki 0.09
drug1853 Placebo oral tablet Wiki 0.07
drug262 Azithromycin Wiki 0.06

Correlated MeSH Terms (15)

Name (Synonyms) Correlation
D002658 Developmental Disabilities NIH 0.35
D065886 Neurodevelopmental Disorders NIH 0.25
D002659 Child Development Disorders, Pervasive NIH 0.20
D001321 Autistic Disorder NIH 0.18
D000067877 Autism Spectrum Disorder NIH 0.14
D045169 Severe Acute Respiratory Syndrome NIH 0.09
D018352 Coronavirus Infections NIH 0.09
D013577 Syndrome NIH 0.08
D001523 Mental Disorders NIH 0.08
D004194 Disease NIH 0.06
D011014 Pneumonia NIH 0.06
D011024 Pneumonia, Viral NIH 0.04
D014777 Virus Diseases NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.03
D007239 Infection NIH 0.02

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0000717 Autism HPO 0.18
HP:0000729 Autistic behavior HPO 0.14
HP:0002090 Pneumonia HPO 0.06

There are 8 clinical trials

Clinical Trials

1 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.

NCT04343248 COVID-19 Viral Respiratory Illnesses Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex

Primary Outcomes

Description: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.

Measure: Symptomatic laboratory-confirmed COVID-19

Time: up to 6 weeks

Description: The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.

Measure: Symptomatic laboratory-confirmed VRI

Time: up to 6 weeks

2 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

3 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers

NCT04359680 COVID-19 Viral Respiratory Illnesses Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex

Primary Outcomes

Measure: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.

Time: Up to 6 weeks

Measure: The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.

Time: Up to 6 weeks

4 Novel Treatment Regimens in Treatment of COVID-19

Azithromycin has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

NCT04382846 COVID Corona Virus Infection Drug: Nitazoxanide Drug: Ivermectin Drug: Chloroquine Drug: Azithromycin
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: the number of patients with virological cure

Measure: Number of patients with virological cure

Time: 6 months

5 Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day, Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Non-critical Condition

This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg TID) to treat hospitalized patients with non-critical COVID-19.

NCT04423861 covid19 Drug: Nitazoxanide Drug: Placebo

Primary Outcomes

Description: PCR will be done to evaluate the change in viral load

Measure: Viral load

Time: day 1, 4, 7, 14 and 21

Secondary Outcomes

Description: Time to wean off oxygen supplementation

Measure: Evolution of acute respiratory syndrome

Time: 21 days

Description: WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)

Measure: Change in Clinical Condition

Time: 21 days

Description: Time to be discharged from hospital

Measure: Hospital discharge

Time: 21 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality within 21-days

Time: 21 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Need of mechanical ventilation

Time: 21 days

6 Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day for Post Exposure Prophylaxis of COVID-19 in Subjects From Vulnerable Communities

The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable communities that had direct contact with patients diagnosed with the disease.

NCT04435314 covid19 Drug: Nitazoxanide Drug: Placebo

Primary Outcomes

Description: PCR will be done to evaluate infection

Measure: The proportion of subjects with laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study

Time: 28 days

Secondary Outcomes

Description: Number of participants with treatment-related adverse events

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 28 days

Description: Symptomatic PCR positive subjects

Measure: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the study

Time: 28 days

Description: Asymptomatic PCR will be done to evaluate infection

Measure: The proportion of subjects with asymptomatic laboratory-confirmed COVID identified after the start of treatment and before the end of the study

Time: 28 days

Description: Subject adherence to treatment will be assessed through study diary record

Measure: Treatment adherence

Time: 7 days

Description: Proportion of patients with severe condition

Measure: Disease complication

Time: 28 days

Description: Proportion of patient that needed undergo an unscheduled visit

Measure: Incidence of subjects that underwent unscheduled visit

Time: 28 days

7 Prospective, Randomized, Double-blind, Parallel, Placebo Controlled Study to Evaluate the Safety and Efficacy of Nitazoxanide 600 mg Three Times a Day to Treat Ambulatory Adult Subjects Diagnosed With COVID-19 With Mild Symptoms Assisted in the Public Health System of the City of Mesquita -RJ

The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only.

NCT04441398 covid19 Drug: Nitazoxanide Drug: Placebo

Primary Outcomes

Description: Symptoms will be assessed using a 5 point scale (1- excellent, 2- good, 3- fair, 4 - poor 5 - very poor).

Measure: Change in signs and symptoms scale

Time: 21 days

Secondary Outcomes

Description: Number of participants with treatment-related adverse events

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 21 days

Description: Change in clinical condition - WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)

Measure: The proportion of subjects hospitalized after start of treatment and before the end of the study

Time: 21 days

Description: Change in clinical condition - WHO Ordinal Scale for Clinical Improvement that measures illness severity over time (0=uninfected; ambulatory, no limitation of activities=1; ambulatory, limitation of activities=2, hospitalized no oxygen therapy=3; hospitalized oxygen by mask or nasal prongs=4; hospitalized non invasive ventilation or high-flow oxygen=5; hospitalized intubation or mechanical ventilation=6; hospitalized ventilation + additional organ support=7; death=8)

Measure: The proportion of subjects that need mechanical ventilation after start of treatment and before the end of the study

Time: 21 days

Description: Time required (days) to full symptom recovery

Measure: Duration of symptoms

Time: 21 days

Description: Evaluation of change in acute respiratory syndrome

Measure: Rate of mortality within 21-days

Time: 21 days

8 Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study

Evaluation of the efficacy and safety of NTX in adult patients (≥18 years and <60 years), with SARS-CoV-2 infection with mild symptoms of COVID-19, compared to a placebo control arm. 135 patients will be randomized to either Nitazoxanide (n=90) or placebo (n=45) (2:1). Simple blind design. Primary endpoint: eradication of virus from patients' respiratory tract secretions by the 7th day of treatment.

NCT04463264 COVID-19 Drug: Nitazoxanide Drug: Placebo
MeSH:Infection Virus Diseases

Primary Outcomes

Description: Erradication will be considered a reduction of the viral load on day 7 greater than 35% with respect to placebo. Extraction of genomic material will be performed using a QIAgen mini kit (QIAmp viral RNA) validated by the CDC (United States Center for Disease Control and Prevention (https://www.fda.gov/media/134922/download) (CDC-006-00019) Viral load will be quantified with the following detection kits: Commercial Kit: PCR-EUA-CDC-nCoV-IFU. Commercial KIT SENTINEL - STAT-NAT Covid 19B (Berlín). Rational: In mild cases of COVID-19, 50% of the patients eradicated the virus within a period of 3 weeks, 25% eradicated the virus before the 13th day, 75% during the first month and the rest were " late eradicators." This latter subgroup of patients has been associated with severe cases of COVID-19 disease.

Measure: Eradication of SARS COV-2 from patients' respiratory tract secretions by treatment day 7th.

Time: 7 day

Secondary Outcomes

Description: Consequently, in mild cases, viral eradication will likely occur more frequently during the first to second week of COVID-19 disease; less than 15% could eradicate the virus during the first week of symptom onset. From an epidemiological point of view, increasing the viral eradication rate from less than 15% to more than 35% during the first two weeks of treatment would be clinically relevant.(seven), 14 (fourteen) and 35 (thirty-five) after starting treatment compared to the baseline measurement.

Measure: Comparative decrease of the viral load

Time: 3 - 35 days

Description: Clinical improvement according to the WHO COVID-19 ordinal scale. Minimun 0 (zero), (best), maximum 8 (eight) (worst)

Measure: Clinical improvement

Time: 1 - 35 days

Description: Percentage of pneumonia patients meeting severity criteria.

Measure: Pneumonia patients meeting severity criteria.

Time: 1 - 35 days

Description: Number of days with fever (axillary temperature higher than 37.5°C).

Measure: Number of days with fever

Time: 1 - 35 days

Other Outcomes

Description: Percentage of patients requiring mechanical ventilation through orotracheal intubation (OT) and/or ICU hospitalization.

Measure: Patients requiring mechanical ventilation

Time: 1 - 35 days

Description: Mortality rate.

Measure: Mortality rate.

Time: 1- 35 days

Description: Lymphocyte recovery (absolute lymphocyte count > 1000 / mm3).

Measure: Lymphocyte recovery

Time: 7 day

Description: Days of ICU hospitalization.

Measure: ICU hospitalization.

Time: 1 - 35 days

Description: Oxygen saturation (SpO2) > 92% (at ambient FiO2).

Measure: Oxygen saturation

Time: 1 - 35 days

Description: Days of hospitalization

Measure: Days of hospitalization

Time: 1 - 35 days

Description: Respiratory rate per minute (in afebrile state conditions).

Measure: Respiratory rate

Time: 1 - 35 days

No related HPO nodes (Using clinical trials)